News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Derma Sciences, Inc. (DSCI) Closes $29 Million Private Placement Financing



6/27/2011 11:11:32 AM

PRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (“Derma Sciences” or “the Company”) (Nasdaq:DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced it has closed its previously announced private placement. The financing was led by leading institutional healthcare investors Jennison Associates LLC, RA Capital Management and Deerfield Management. In the offering, the Company raised $29,075,000 by issuing 3,524,239 shares of common stock and 1,762,118 warrants at an aggregate purchase price of $8.25 per share. The warrants have a five year life and are exercisable at a price of $9.90 per share. Net proceeds from this financing will be used to advance the Company’s pharmaceutical product DSC127 into Phase 3 trials for the treatment of diabetic foot ulcers, to hire additional salespeople for the Company’s advanced wound care products, to repay debt and for general corporate purposes.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES